Mersana Therapeutics, Inc. (MRSN)

2.9400 +0.0900 (+3.16%) At close: 04:00PM EDT

Mersana Therapeutics, Inc.

840 Memorial Drive
Cambridge, MA 02139
United States
617 498 0020
https://www.mersana.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 123

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Martin H. Huber M.D.	President, CEO & Director	44k	N/A	1961
Mr. Brian C. DeSchuytner	Senior VP, CFO & COO	626.32k	N/A	1978
Dr. Timothy B. Lowinger Ph.D.	Senior VP and Chief Science & Technology Officer	666.3k	199.82k	1964
Ms. Alejandra Veronica Carvajal J.D.	Senior VP, Secretary & Chief Legal Officer	606.51k	N/A	1974
Mr. Mikhail Papisov Ph.D.	Co-Founder	N/A	N/A	N/A
Mr. Ashish Mandelia	Chief Accounting Officer	N/A	N/A	1975
Mr. Jason Fredette	Senior Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Chuck Miller	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Mr. Marc Damelin	Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop.	N/A	N/A	N/A
Dr. Tushar Misra Ph.D.	Senior VP & Chief Manufacturing Officer	485.89k	N/A	1961

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Mersana Therapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.